These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1623277)

  • 21. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
    Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
    Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits of Gd-DTPA for MR imaging of intracranial abnormalities.
    Hesselink JR; Healy ME; Press GA; Brahme FJ
    J Comput Assist Tomogr; 1988; 12(2):266-74. PubMed ID: 3351041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective enhancement of experimental rat brain tumors with Gd-TPPS.
    Bockhorst K; Els T; Hoehn-Berlage M
    J Magn Reson Imaging; 1994; 4(3):451-6. PubMed ID: 8061446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gd-DTPA administered MR imaging of intracranial mass lesions: a comparison with CT and precontrast MR.
    Mihara F; Hirakata R; Hasuo K; Yasumori K; Yoshida K; Kuroiwa T; Masuda K; Fukui M
    Radiat Med; 1989; 7(5):227-35. PubMed ID: 2629036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the clinical safety of gadodiamide injection, a new nonionic MRI contrast medium for the central nervous system: a European perspective.
    Aslanian V; Lemaignen H; Bunouf P; Svaland MG; Borseth A; Lundby B
    Neuroradiology; 1996 Aug; 38(6):537-41. PubMed ID: 8880714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain lesion contrast in MR imaging. Dependence on field strength and concentration of gadodiamide injection in patients and phantoms.
    Akeson P; Vikhoff B; Ståhlberg F; Holtås S
    Acta Radiol; 1997 Jan; 38(1):14-8. PubMed ID: 9059395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reperfusion and irreversible myocardial injury: identification with a nonionic MR imaging contrast medium.
    Saeed M; Wendland MF; Takehara Y; Masui T; Higgins CB
    Radiology; 1992 Mar; 182(3):675-83. PubMed ID: 1535880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved contrast of enhancing brain lesions on postgadolinium, T1-weighted spin-echo images with use of magnetization transfer.
    Finelli DA; Hurst GC; Gullapali RP; Bellon EM
    Radiology; 1994 Feb; 190(2):553-9. PubMed ID: 8284415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular responses after ionic and nonionic magnetic resonance contrast media in rats with acute myocardial infarction.
    Li HT; Saeed M; Wendland MF; Higgins CB
    Invest Radiol; 1993 Jan; 28(1):11-9. PubMed ID: 8425847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MR imaging of pituitary region lesions with gadodiamide injection.
    Hald JK; Skalpe IO; Bakke SJ; Nakstad PH
    Acta Radiol; 1994 Jan; 35(1):65-9. PubMed ID: 8305277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors.
    Niendorf HP; Laniado M; Semmler W; Schörner W; Felix R
    AJNR Am J Neuroradiol; 1987; 8(5):803-15. PubMed ID: 2823588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-dependency in brain lesion enhancement with gadodiamide injection.
    Akeson P; Nordström CH; Holtås S
    Acta Radiol; 1997 Jan; 38(1):19-24. PubMed ID: 9059396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Static, dynamic and first-pass MR imaging of musculoskeletal lesions using gadodiamide injection.
    Verstraete KL; Vanzieleghem B; De Deene Y; Palmans H; De Greef D; Kristoffersen DT; Uyttendaele D; Roels H; Hamers J; Kunnen M
    Acta Radiol; 1995 Jan; 36(1):27-36. PubMed ID: 7833165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiation of hepatic hemangiomas from metastases by dynamic contrast-enhanced MR imaging.
    Hamm B; Fischer E; Taupitz M
    J Comput Assist Tomogr; 1990; 14(2):205-16. PubMed ID: 2312848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of the magnetic resonance contrast agent gadodiamide in the central nervous system. Results of a multicenter trial.
    Sze G; Brant-Zawadzki M; McNamara MT; Haughton VM; Kumar AJ; Maravilla KR; Aisen AM; Dreisbach JN; Bradley WG; Weinreb JC
    Invest Radiol; 1993 Mar; 28 Suppl 1():S49-55. PubMed ID: 8486504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reverse enhancement of hemorrhagic brain lesions on postcontrast MR: detection with digital image subtraction.
    Gaul HP; Wallace CJ; Crawley AP
    AJNR Am J Neuroradiol; 1996 Oct; 17(9):1675-80. PubMed ID: 8896621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detectability of small liver metastases with gadolinium BOPTA.
    Runge VM; Lee C; Williams NM
    Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Squamous cell carcinoma of the oral cavity: MR findings and value of T1-versus T2-weighted fast spin-echo images.
    Yasumoto M; Shibuya H; Takeda M; Korenaga T
    AJR Am J Roentgenol; 1995 Apr; 164(4):981-7. PubMed ID: 7726062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of pseudocapsule of renal cell carcinoma with MR imaging and CT.
    Yamashita Y; Honda S; Nishiharu T; Urata J; Takahashi M
    AJR Am J Roentgenol; 1996 May; 166(5):1151-5. PubMed ID: 8615260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gd-DTPA adrenal gland enhancement at 1.5 T.
    Small WC; Bernardino ME
    Magn Reson Imaging; 1991; 9(3):309-12. PubMed ID: 1881248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.